Shockwave Announces Joint Venture In China with Genesis MedTech Group

Shockwave Medical, Inc., a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has signed an agreement to form a joint venture with Genesis MedTech Group to introduce IVL to the Chinese market. Together, Shockwave and Genesis strive to bring coronary and peripheral IVL products to patients in mainland China.

The joint venture will benefit from Genesis MedTech's strong track record and expertise in the commercialization of medical devices as well as industry-leading sales network in China. Genesis MedTech's China capabilities are complementary to Shockwave's global expertise in the development, manufacture, and sale of IVL products.

"Shockwave is a pioneer in their field and our partnership will be of long-term strategic significance not only for Genesis MedTech, but also for the medical community in China," said Warren Wang, Chairman and Chief Executive Officer of Genesis MedTech International.  "We share Shockwave's passion for developing technologies to serve unmet medical needs and are confident that together we can help many patients in China who suffer from calcified arterial disease." 

"This joint venture represents another step in the continuation of our strategy to ensure that patients globally have access to IVL and to do so with a strong, local presence.   We are pleased to have a partner with such a solid, established track record in developing and commercializing innovative technologies in China," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical, "We look forward to joining forces with Warren and his team as we work together to bring IVL to the large and growing Chinese interventional market."

According to the agreement, the new joint venture will be named Genesis Shockwave Private Limited and enables the commercialization of both imported Shockwave-branded IVL products as well as IVL products that are locally developed, manufactured, and branded by Genesis Shockwave Private Limited.  The creation of the joint venture is subject to the satisfaction of certain closing conditions, including the approval of relevant government authorities in China.

About Shockwave Medical, Inc.

Shockwave is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which the company refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes. 

About Genesis MedTech Group

Genesis MedTech Group is a medical device company headquartered in Singapore. Founded by a group of professionals and entrepreneurs with MedTech experience globally and in Asia, the company's product portfolio focuses on value segment multi-therapy medical device products for emerging markets with sales and distribution through its established commercial network. Genesis MedTech Group covers the entire industry value chain of research and development, production, quality management, supply chain, marketing, and sales.